posted on 2019-06-13, 11:12authored byD Aravani, GE Morris, PD Jones, HK Tattersall, E Karamanavi, MA Kaiser, RB Kostogrys, M Ghaderi Najafabadi, SL Andrews, M Nath, S Ye, EJ Stringer, NJ Samani, TR Webb
BACKGROUND: Genome-wide association studies have identified chromosome 14q32 as a locus for coronary artery disease. The disease associated variants fall in a hitherto uncharacterised gene called Hedgehog Interacting Protein Like 1 (HHIPL1), which encodes a sequence homologue of an antagonist of hedgehog signaling. The function of HHIPL1 and its role in atherosclerosis is unknown. METHODS: HHIPL1 cellular localization, interaction with Sonic Hedgehog (SHH) and influence on hedgehog signaling were tested. HHIPL1 expression was measured in coronary artery disease relevant human cells and protein localization was assessed in wild-type and Apoe-/- mice. Human aortic smooth muscle cell phenotypes and hedgehog signaling were investigated following gene knockdown. Hhipl1-/- mice were generated and aortic smooth muscle cells collected for phenotypic analysis and assessment of hedgehog signaling activity. Hhipl1-/- mice were bred onto both the Apoe-/- and Ldlr-/- knockout strains and the extent of atherosclerosis was quantified following 12 weeks of high fat diet. Cellular composition and collagen content of aortic plaques was assessed by immunohistochemistry. RESULTS: In vitro analyses revealed that HHIPL1 is a secreted protein that interacts with SHH and increases hedgehog signaling activity. HHIPL1 expression was detected in human smooth muscle cells and in smooth muscle within atherosclerotic plaques of Apoe-/- mice. The expression of Hhipl1 increased with disease progression in aortic roots of Apoe-/- mice. Proliferation and migration was reduced in Hhipl1 knockout mouse and HHIPL1 knockdown aortic smooth muscle cells and hedgehog signaling was decreased in HHIPL1 deficient cells. Hhipl1 knockout caused a reduction of more than 50% in atherosclerosis burden on both Apoe-/- and Ldlr-/- knockout backgrounds and lesions were characterized by reduced smooth muscle cell content. CONCLUSIONS: HHIPL1 is a secreted proatherogenic protein that enhances hedgehog signaling and regulates smooth muscle cell proliferation and migration. Inhibition of HHIPL1 protein function might offer a novel therapeutic strategy for coronary artery disease.
The research leading to these results has received funding from the European Union Seventh
Framework Programme FP7/2007-2013 under grant agreement number HEALTH-F2-2013-
601456, a Transatlantic Networks of Excellence Award (12CVD02) from The Leducq
Foundation and the British Heart Foundation (SP/18/8/33620) as a partner of the European
Research Area Network on Cardiovascular Diseases (ERA-CVD) druggable-MI-genes
(01KL1802) and supported by the UK National Institute for Health Research (NIHR)
Leicester Biomedical Research Centre. NJS is a UK NIHR Senior Investigator. G.E.M, S.Y
and T.R.W are funded by the British Heart Foundation (SP/16/4/32697).
/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Cardiovascular Sciences
VoR (Version of Record)
American Heart Association, Lippincott, Williams & Wilkins